XM does not provide services to residents of the United States of America.
B
B

Biogen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds By Christy Santhosh June 13(Reuters) - Some 4% of U.S. adults aged 65 and older say they have been diagnosed with dementia, a rate that reached 13% for those at least 85-years old, according to a report of a national survey released on Thursday. The report issued by the U.S.
B

Biogen executive plays down looming competition for its Alzheimer's drug

UPDATE 1-Biogen executive plays down looming competition for its Alzheimer's drug Adds executive comments in paragraphs 3-4, analysts' comments in paragraphs 9-11 By Sriparna Roy June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
B
G

Biogen executive says its Alzheimer's drug will do well in market despite competition

Biogen executive says its Alzheimer's drug will do well in market despite competition June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editi
B

Alzheimer's is a $100 bln pharma opportunity, says HSBC

BUZZ-Alzheimer's is a $100 bln pharma opportunity, says HSBC ** Brokerage HSBC says Biogen BIIB.O and partner Eisai's 4523.T Leqembi and Eli Lilly's LLY.N donanemab could start shaping a $100 bln U.S. market for Alzheimer's disease treatments ** Leqembi was given full approval by the U.S. FDA last year and donanemab won an unanimous endorsement by an advisory panel on Monday ** HSBC says overwhelming support for donanemab's approval highlights not only a positive benefit-risk profile for the new
B

Japan's Nikkei gains on chip shares boost; Fed policy in focus

Japan's Nikkei gains on chip shares boost; Fed policy in focus Updates with closing levels By Brigid Riley TOKYO, June 11 (Reuters) - Japan's Nikkei share average closed at a two-month peak on Tuesday as heavyweight chip shares tracked their Wall Street peers higher, while investors braced for the Federal Reserve's p olicy decision later this week . S entiment was up during early Tokyo trading after the S&P 500 and Nasdaq both logged record closing highs overnight .
B
U
J
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.